Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stuart Jay Schnitt, M.D.

Co-Author

This page shows the publications co-authored by Stuart Schnitt and Tari King.
Connection Strength

2.672
  1. ASO Visual Abstract: Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. Ann Surg Oncol. 2022 Mar; 29(3):1668-1669.
    View in: PubMed
    Score: 0.247
  2. ASO Visual Abstract: Limited Reporting of Histopathologic Details in a Multi-Institutional Academic Cohort of Phyllodes Tumors: Time for Standardization. Ann Surg Oncol. 2021 12; 28(Suppl 3):465-466.
    View in: PubMed
    Score: 0.243
  3. Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. Ann Surg Oncol. 2022 Mar; 29(3):1660-1667.
    View in: PubMed
    Score: 0.240
  4. Limited Reporting of Histopathologic Details in a Multi-Institutional Academic Cohort of Phyllodes Tumors: Time for Standardization. Ann Surg Oncol. 2021 Nov; 28(12):7404-7409.
    View in: PubMed
    Score: 0.234
  5. Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer. Mod Pathol. 2021 05; 34(5):875-882.
    View in: PubMed
    Score: 0.226
  6. The Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In Situ in Patients with Intraductal Papilloma without Atypia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 034). Ann Surg Oncol. 2021 May; 28(5):2573-2578.
    View in: PubMed
    Score: 0.225
  7. American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications. Ann Diagn Pathol. 2020 Apr; 45:151481.
    View in: PubMed
    Score: 0.215
  8. Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations. Mod Pathol. 2020 07; 33(7):1287-1297.
    View in: PubMed
    Score: 0.213
  9. Evaluation of Breast and Axillary Lymph Node Specimens in Breast Cancer Patients Treated With Neoadjuvant Systemic Therapy. Adv Anat Pathol. 2019 Jul; 26(4):221-234.
    View in: PubMed
    Score: 0.206
  10. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Ann Surg Oncol. 2019 Nov; 26(12):3846-3855.
    View in: PubMed
    Score: 0.205
  11. Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). JNCI Cancer Spectr. 2018 Nov; 2(4):pky063.
    View in: PubMed
    Score: 0.199
  12. Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). Ann Surg Oncol. 2016 Mar; 23(3):722-8.
    View in: PubMed
    Score: 0.160
  13. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2021 Nov; 28(12):7347-7355.
    View in: PubMed
    Score: 0.058
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.